奥沙利铂联合卡培他滨治疗进展期胃癌的疗效及安全性评估

Efficacy and safety of oxaliplatin combined with capecitabine in the treatment of patients with advanced gastric cancer

目的探讨奥沙利铂联合卡培他滨治疗进展期胃癌的临床疗效及安全性。方法选取2012年5月至2015年5月间收治的80例进展期胃癌患者,根据随机数字表法分为观察组和对照组,每组各40例。观察组患者接受奥沙利铂联合卡培他滨治疗,对照组患者接受ECF方案化疗(表柔比星+顺铂+氟尿嘧啶),比较两组患者的临床疗效、不良反应以及治疗前后的生活质量。结果与对照组相比,观察组患者治疗的总有效率明显升高,差异有统计学意义(P<0.05);观察组患者胃肠道反应、骨髓抑制等不良作用发生率均显著降低,差异有统计学意义(P<0.05);观察组患者治疗后生活质量各维度及总分均明显增高,差异有统计学意义(P<0.05)。结论奥沙利铂联合卡培他滨治疗进展期胃癌具有疗效显著、毒副作用少等特点,可明显提高患者的生活质量,值得临床推广。

Objective To study the clinical efficacy and safety of the treatment of oxaliplatin combined with capecitabine in the treatment of patients with advanced gastric cancer. Methods The 80 patients with advanced gastric cancer in Huludao Central Hospital during the period from May 2012 to May2015 were enrolled int the study. They were randomized into the observation group and the control group,40 cases in each group. The patients in the observation group accepted oxaliplatin combined with capecitabine treatment and those in the control group accepted ECF（ epirubicin ＋ cisplatin ＋ fluorouracil） chemotherapy.The clinical efficacy,toxicity,and the life quality on pre- and post-treatment in the two groups were compared. Results Compared with the control group,the total effective rate was significantly increased in the observation group,with statistical difference（ P〈0. 05）; the toxicity incidence of gastrointestinal reactions and bone marrow suppression were obviously reduced in the observation group,with statistical difference（ P〈0. 05）; the each dimension and total scores of life quality on post-treatment were significantly increased in the observation group,with statistical difference（ P〈0. 05）. Conclusions The treatment of oxaliplatin combined with capecitabine for advanced gastric cancer has the significant efficacy and less toxicity,and obviously improve the patients＇ life quality. It is worthy of clinical promotion.